Abstract 5706
Background
Surgery for breast cancer liver metastases (BCLM) remains controversial. Recently, histological growth pattern (HGP), defined as replacement (rHGP) or desmoplastic (dHGP), has been demonstrated of prognostic value in patients operated for colorectal liver metastases. In BCLM, the types of HGP and their prognostic values have not been determined. We aimed to characterize HGPs in a series of patients undergoing liver resection for BCLM and correlate these patterns with postoperative outcomes.
Methods
A series of 74 patients operated for BCLM was reviewed. Clinicopathologic variables, overall and disease-free survivals (OS and DFS) were analyzed. HGP could not be evaluated in 37 cases, due to exclusive radiofrequency treatment (N = 22), complete pathological response (N = 9) or unavailability of tissue sections (N = 6). HGP was assessed in archival H&E stained tissue sections, according to international consensus guidelines in 37 patients. The proportions of rHGP and dHGP were determined in each metastasis. Patients were categorized as pure (100% rHGP or dHGP) or dominant phenotype (>50% rHGP or dHGP, on the entire tumor/normal liver interface). In case of multiple metastases, mean HGP was calculated. All these factors were correlated with OS and DFS.
Results
After a mean postoperative follow-up of 81 months, 5-years OS and DFS in global population were 49.7% and 22.7%, respectively. No clinicopathologic preoperative factor was found to be predictive for OS or DFS. Among the 37 patients analyzed for HGP, 17 were pure rHGP (46%), 10 dominant rHGP (27%), 9 dominant dHGP (24.3%) and 1 pure dHGP. Five-years OS and DFS were significantly reduced in patients with pure rHGP, respectively of 20.3 and 0% (all patients recurring within 2 years) as compared with patients with any dHGP component, respectively of 63 and 45% (p = 0.03 and <0.003). No other parameter (patient, primary tumor and BCLM characteristics) was significantly different between the patients with pure rHGP and those with any dHGP component.
Conclusions
In this series of patients undergoing surgical resection for BCLM, the large majority of metastases displayed pure or dominant rHGP. Pure rHGP appears as a strong negative prognostic factor for postoperative outcome in these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vincent Donckier.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract